Craft

Advanced
Baudax Bio

Baudax Bio

Stock Price

$0.2

2024-07-18

Market Capitalization

$8.1 M

2024-07-18

Revenue

$1.3 M

FY, 2022

Baudax Bio Summary

Company Summary

Overview
Baudax Bio is a pharmaceutical company that focuses on developing and commercializing products for patients in acute care settings. Its key product candidate is IV meloxicam for the acute care markets.
Type
Public
Status
Active
Founded
2019
HQ
Malvern, PA, US | view all locations
Website
https://www.baudaxbio.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Table of Contents

Key People

  • Gerri Henwood, President, Chief Executive Officer

    • William L. Ashton, Director

      • Winston J. Churchill, Director

        • Arnold Baskies, Director

          LocationsView all

          1 location detected

          • Malvern, PA HQ

            United States

            490 Lapp Rd

          Baudax Bio Financials

          Summary Financials

          Net income (Q3, 2023)
          ($1.9M)
          Cash (Q3, 2023)
          $363.0K
          EBIT (Q3, 2023)
          ($1.8M)
          Enterprise value
          $12.0M

          Competitors and Similar Companies

          Compare competitors

          Footer menu

          Product

          Solutions

          Resources

          Company

          © Craft.co 2026
          Share price data provided by IEX